Affordable Care Act, Biosimilar, Health Insurance
ACA Supreme Court Deliberations and Any Impact on Biosimilars?
28
Nov
Nov
If the court strikes down the ACA entirely, biosimilars on the U.S. market or in the FDA approval pipeline would have to either be grandfathered in or face a regulatory wind-down